Related Experiment Video
Updated: Oct 1, 2025
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
Published on: June 7, 2020
Integration of molecular imaging in the personalized approach to neuroendocrine tumors
Maria A Muros1, Tarik Aroui2, Daniel Rivas-Navas2
1Department of Nuclear Medicine, Virgen de las Nieves Hospital, Granada, Spain - mangustias.muros.sspa@juntadeandalucia.es.
Abstract:
NETs lesions can be difficult to characterize with conventional anatomic imaging (CT and MRI). Functional imaging techniques, and especially PET imaging, are very useful for detecting small neuroendocrine tumors that would not be seen with other techniques. The role of nuclear medicine in the localization, staging, restaging, treatment and monitoring of neuroendocrine tumors (NETs) has become progressively more relevant due to: the availability of tracers on new targets, tracers for positron emission tomography (PET); the development of cyclotrons and generators that allow this availability; as well as to hybrid systems (SPECT/CT, PET/CT and PET/MRI) that, by joining the functional and anatomical image, improve the quality of the images. Teragnosis, a new emerging therapy, in NET used receptor-mediated or nonreceptor- mediated mechanism to facilitate penetration and high-affinity binding between the radiopharmaceutical and the tumor cell. Teragnosis offers the possibility of personalized targeted radionuclide therapy.
Insights
Nuclear medicine, particularly PET imaging, enhances the detection and management of neuroendocrine tumors (NETs). Emerging theranostics offer personalized radionuclide therapy for NETs.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiochemistry
Background:
- Conventional imaging like CT and MRI struggle to characterize neuroendocrine tumor (NET) lesions.
- Functional imaging, especially Positron Emission Tomography (PET), excels at detecting small NETs missed by other methods.
Purpose of the Study:
- To highlight the increasing importance of nuclear medicine in the comprehensive management of neuroendocrine tumors (NETs).
- To discuss advancements in PET tracers, hybrid imaging systems, and theranostics for NETs.
Main Methods:
- Review of advancements in PET tracers and hybrid imaging systems (SPECT/CT, PET/CT, PET/MRI).
- Exploration of theranostics, a novel therapeutic approach for NETs utilizing targeted radiopharmaceuticals.
Main Results:
- PET imaging significantly improves the detection of small NETs compared to conventional techniques.
- Hybrid imaging systems enhance diagnostic accuracy by combining functional and anatomical data.
- Theranostics demonstrate potential for personalized targeted radionuclide therapy in NET patients.
Conclusions:
- Nuclear medicine plays a crucial and expanding role in the localization, staging, treatment, and monitoring of NETs.
- Advancements in PET tracers, hybrid imaging, and theranostics are revolutionizing NET patient care.
- Theranostics represent a promising frontier for personalized, targeted radionuclide therapy in neuroendocrine tumors.
